IP Library Granted Patent US 9,637,777
Granted Patent B2
US 9,637,777 · App. 14/257,294 · Granted May 2, 2017

Optimization of gene expression analysis using immobilized capture probes

Inventors: Michael Seul (Fanwood, NJ); Sukanta Banerjee (Pennington, NJ); Jiacheng Yang (Hillsboro, NJ); Tatiana Vener (Stirling, NJ)
Assignee: BioArray Solutions, Ltd.
C12Q1/6832C12Q1/6809C12Q1/6834C12Q1/6837B01J2219/00459B01J2219/00576B01J2219/00608B01J2219/00648B01J2219/00722
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,637,777
App. No.
14/257,294
Granted
May 2, 2017
Kind
B2
Abstract

Disclosed are methods of multiplexed analysis of oligonucleotides in a sample, including a method of preventing a significant reduction in duplexes detectable in a hybridization assay involving (i) selecting probe lengths for sets of oligonucleotide probes, wherein probes include different subsequences such that at least one subsequence is complementary to a subsequence in a cognate target; wherein probes for longer cognate targets are longer in length than probes for shorter cognate targets, (ii) selecting, for each set of probes, a density of oligonucleotides probes attached per unit area on a solid phase carrier which is below a limit at which the significant reduction in detectable duplexes is predicated to take place, (iii) producing the probes and affixing them to different solid phase carriers at the selected density, and (iv) annealing targets to the probes, wherein signal intensities of probes and targets of different lengths are about the same.

Claims (14)

1. A method of preventing a significant reduction in duplexes detectable in a hybridization assay, the method comprising:

(i) selecting probe lengths for sets of oligonucleotide probes, wherein probes comprise different subsequences such that at least one subsequence is complementary to a subsequence in a cognate target; wherein probes for longer cognate targets are longer in length than probes for shorter cognate targets;

(ii) selecting, for each set of probes, a density of probes attached per unit area on a solid phase carrier which is below a limit at which said significant reduction in detectable duplexes is predicated to take place;

(iii) producing said probes and affixing said probes to different solid phase carriers at the selected density; and

(iv) annealing targets to the probes, wherein signal intensities of probes and targets of different lengths are about the same.

2. The method of claim 1 , wherein the density for longer probes is lower than the density for shorter probes.

3. The method of claim 1 , wherein the subsequence of the cognate target is located near the 5′ end of the target.

4. The method of claim 1 further comprising attaching a bifunctional polymeric moiety to the solid phase carriers and then attaching said probes to said bifunctional polymeric moiety.

5. The method of claim 4 , wherein the surface area of the bifunctional polymeric moiety, when attached to the solid phase carriers, is known.

6. The method of claim 4 , wherein said bifunctional polymeric moiety is a polyethylene glycol-having a known approximate molecular weight.

7. The method of claim 4 , wherein said bifunctional polymeric moiety is a protein.

8. The method of claim 7 , wherein the protein is neutravidin.

9. The method of claim 1 , wherein adjacent probe-target complexes attached to the surface do not overlap each other.

10. The method of claim 1 , wherein the probes and the targets are both either RNA or DNA.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Mar 15, 2023
From: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
To: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS, INC.
Reel/Frame 063090/0033 →
RELEASE OF SECURITY INTEREST Recorded Mar 15, 2023
From: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT
To: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS, INC.
Reel/Frame 063090/0111 →
RELEASE OF PATENT SECURITY INTERESTS Recorded Jul 2, 2020
From: CITIBANK, N.A.
To: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; IMMUCOR GTI DIAGNOSTICS, INC.; SIRONA GENONICS, INC.
Reel/Frame 053121/0935 →
SECURITY INTEREST Recorded Jul 2, 2020
From: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 053119/0135 →
SECURITY INTEREST Recorded Jul 2, 2020
From: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS INC.
To: ALTER DOMUS (US) LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 053119/0152 →
SECURITY AGREEMENT Recorded Jul 21, 2017
From: BIOARRAY SOLUTIONS LTD.; IMMUCOR GTI DIAGNOSTICS, INC.
To: CITIBANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 043288/0785 →
Continuity (6)
Continuation 12480215 · Jun 8, 2009
Continuation 10974036 · Oct 26, 2004
Provisional Application 60516611 · Oct 28, 2003
Provisional Application 60544533 · Feb 14, 2004
Related Publication 20160215327A1 · Jul 28, 2016
Related Publication 20170088885A9 · Mar 30, 2017